• 26 Apr, 2026
• SendSlim Team
• No comment

Tirzepatide vs Semaglutide: Key Differences Explained

Two Powerful Weight Loss Medications — What You Need to Know

If you have been researching medical weight loss options, you have likely heard the names tirzepatide and semaglutide. Both are injectable medications that have shown strong results in clinical trials for weight management. They work in similar ways, but there are important differences between them. Understanding those differences can help you have a more informed conversation with a licensed clinician about which option may be right for you.

Neither medication is a magic fix, and results vary from person to person. However, both have changed the landscape of medical weight loss in meaningful ways. This article breaks down what each drug does, how they differ, and what the research says about each one.

How These Medications Work

Both tirzepatide and semaglutide belong to a class of medications that mimic natural hormones in the body. These hormones are released after you eat. They signal your brain that you are full, slow down how fast your stomach empties, and help regulate blood sugar levels. This combination helps reduce appetite and calorie intake over time.

Semaglutide works by targeting one hormone receptor called GLP-1 (glucagon-like peptide-1). Tirzepatide targets two hormone receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Because tirzepatide activates two pathways instead of one, it is sometimes called a “dual agonist.” Researchers believe this dual action may play a role in its effectiveness for weight loss.

Both medications are given as a weekly injection under the skin. They are also both approved by the U.S. Food and Drug Administration (FDA), though for slightly different uses and under different brand names.

FDA Approvals and Brand Names

Semaglutide has been on the market longer. It is sold under the brand name Ozempic for type 2 diabetes management and Wegovy for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. Wegovy received FDA approval for weight management in 2021.

Tirzepatide is sold under the brand name Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The FDA approved Zepbound for weight loss in November 2023, making it the newer of the two options on the market.

It is important to know that these medications are approved for specific uses. A licensed clinician must evaluate your health history, weight, and goals before prescribing either one. They are not appropriate for everyone.

What the Clinical Trials Show

Both medications have been studied in large, well-designed clinical trials. The STEP trials studied semaglutide (Wegovy) and found that participants lost an average of around 15% of their body weight over 68 weeks compared to placebo. These were significant findings that helped lead to FDA approval for weight management.

The SURMOUNT trials studied tirzepatide (Zepbound) and showed even larger average weight reductions — up to about 20-22% of body weight at the highest doses over 72 weeks. A 2023 head-to-head study published in the Journal of the American Medical Association (JAMA) also suggested that tirzepatide may lead to greater weight loss on average compared to semaglutide, though this study used insurance claims data and was not a randomized controlled trial.

It is critical to remember that these are averages from clinical studies. Individual results depend on many factors including diet, physical activity, overall health, and how well someone tolerates the medication. No one can predict exactly how any person will respond.

Side Effects and Tolerability

Because both medications work in similar ways, they share many of the same side effects. The most common side effects for both tirzepatide and semaglutide include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Stomach pain or discomfort

These side effects are most common when starting the medication or increasing the dose. They often improve over time. Both medications are started at a low dose and increased slowly to help reduce these effects. This is called dose escalation.

Both medications carry a boxed warning about a potential risk of thyroid tumors, including thyroid cancer, based on animal studies. Because of this, they are not recommended for people with a personal or family history of certain thyroid conditions. A clinician will review your health history carefully before prescribing either medication. Serious side effects are rare but can include pancreatitis and gallbladder problems.

Cost and Access

Cost is one of the biggest practical differences between these medications for many people. Both tirzepatide and semaglutide can be expensive without insurance coverage. List prices often exceed $1,000 per month, though manufacturer savings programs and pharmacy options can reduce that cost for some people.

Compounded versions of both medications have also become available through certain licensed pharmacies. Compounded medications are not FDA-approved products, and their quality and safety can vary. Always work with a licensed clinician who can guide you toward safe, appropriate options.

If you are in California or Nevada and want convenient access to a licensed clinician who can evaluate whether one of these medications may be appropriate for you, SendSlim offers video and phone visits for just $50 — no insurance required. Getting a professional medical opinion is an important first step before starting any prescription medication.

Which Medication Is Right for You?

There is no one-size-fits-all answer. The right medication depends on your health history, any other conditions you have, your insurance or budget, and how your body responds. Some people do very well on semaglutide. Others may be better candidates for tirzepatide. Only a licensed clinician can make that determination after a proper evaluation.

Both medications are tools to support weight management — not standalone solutions. They work best when combined with healthy eating habits and regular physical activity. A clinician can help you build a full plan around whichever medication you use. SendSlim makes it easy to connect with a licensed provider from home and get personalized guidance without the hassle of a traditional clinic visit.

Conclusion

Tirzepatide and semaglutide are both well-studied, FDA-approved medications that have shown meaningful results in clinical trials for weight management. Tirzepatide targets two hormone receptors while semaglutide targets one, and the available research suggests tirzepatide may produce slightly greater average weight loss. However, both carry similar side effects, similar costs, and both require a prescription from a licensed clinician. The best choice is a personal one, made with the guidance of a qualified medical professional who knows your full health picture.

References

• Jastreboff, Ania M. et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022.
• Wilding, John P.H. et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021.
• Lincoff, A. Michael et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023.
• Rubino, Domenica M. et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” JAMA. 2023.
• U.S. Food and Drug Administration. “FDA Approves New Medication for Chronic Weight Management.” FDA.gov. 2023.